Victor V. Gogolak

Founder and Chief Executive Officer, brings over 30 years of scientific, technology and industry experience to DrugLogic. He was a vice-president in the commercial sector of Booz, Allen & Hamilton (BAH), where he led the company's thrust into drug safety and surveillance. He was responsible for marketing and managing over $13 million annually in project sales; his implementation projects included developing a world-class web-based adverse event reporting system for pharmaceutical companies. Prior to joining BAH, he was one of the six founding shareholders of the Titan Corp., where he developed a line of business supporting government and defense use of technology. He holds a B.S. in physics, a B.S. in philosophy and an M.S. in mathematics from Fordham University.

vgogolak email

Steven A. Wordham

Chief Technology Officer and Vice President of Operations, has spent more than 15 years in the highly charged Information Technology industry, focusing primarily on corporate technical and operations objectives.  Steve has extensive experience with full lifecycle product development, seamlessly merging multiple environments through several acquisitions.  Steve has spent the past 10 years addressing and meeting the demands of the rapidly evolving risk management requirements in the healthcare and pharmaceutical industry.  He works closely with clients, responding to continuously developing product safety objectives, to ensure the optimal utilization of the clients risk management solutions.  In addition, Steve has been instrumental in strengthening several small businesses and startups making funding and successful acquisitions possible.

swordham email

Sheila Weiss, PhD, FISPE

Dr. Sheila Weiss is an epidemiologist with extensive experience in drug safety; pharmacoepidemiology and pharmacovigilance with an emphasis of methodology and data analytics.  Sheila Weiss received a Ph.D. in Epidemiology from Johns Hopkins University. She has worked at the US FDA and the University of Maryland Baltimore, where she was Professor and founding Director of the Center for Drug Safety.  Her research has been focused on the assessment of the use, appropriateness, and safety of medications, vaccines, and other regulated products. Sheila Weiss has consulted on the reengineering of the US and French Drug Safety Systems, worked as a visiting scientist at the National Cancer Institute.  She is a visiting Professor at the Johns Hopkins Bloomberg School of Public Health and a Fellow of the International Society of Pharmacoepidemiology.  Dr. Weiss leads the research consulting program at DrugLogic.

sweiss email

Long Doan

Chief Architect, has over 15 years of experience in the design and implementation of multi-user, real-time communication networks, large-scale data mining, and internet-based content delivery systems. He was in charge of developing the communication platforms for Multicity.com, Inc. and Imvector, LLC; the CrimeStat project for the National Institute of Justice; and the content generation and delivery system for MindQ Publishing, Inc. He was also involved in developing the foundation of multiple real-time communication protocols at NxNetwork, Inc.

ldoan email

Tanya G. Cote

Vice President of Administration, brings four years experience in healthcare-related fields and six years experience in education, public relations and database management. She has worked in educational environments managing student databases and coordinating Financial Aid activities and was responsible for organizing and designing recruitment events and admissions material.  Before that, Tanya spent time in clinical care settings, using her science background and training to work directly with patients in both the medical and dental fields. Tanya received a BA degree from Williams College with extensive course work in Chemistry and Biological Sciences. She has taken additional course work in Molecular Physiology at Harvard and in Microbiology at the University of Maryland.

tcote email